1.25m2] or 100mg [1.25m2&lt

2 trials

Sponsors

NPO Hokkaido Gastrointestinal Cancer Study Group (HGCSG), Fukuoka Tumor Research(FUTURE)

Conditions

Colorectal Canceradvanced/metastatic colorectal cancer

Phase 2

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Active, not recruitingJPRN-UMIN000004882

NPO Hokkaido Gastrointestinal Cancer Study Group (HGCSG)advanced/metastatic colorectal cancer

Start: 2010-03-01Target: 80Updated: 2026-06-29

Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)

Active, not recruitingJPRN-UMIN000006823

Fukuoka Tumor Research(FUTURE)Colorectal Cancer

Start: 2011-12-01Target: 30Updated: 2026-06-29

Related Papers

Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with <i>KRAS</i> exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment.

Journal of Clinical Oncology2016-02-01